Lp-PLA2 Inhibitors Modulate Inflammatory Tone and Oxidative Stress
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases such as ischemia, traumatic brain injury, multiple sclerosis, diabetes, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and cancer lack effective mechanisms to modulate inflammatory tone and oxidative stress, particularly due to the involvement of lipoprotein-associated phospholipase A2 (Lp-PLA2) in inflammatory pathways and oxidative damage.
Innovation Solution
Development of compounds, such as those represented by Formulas (I) and (II), which act as modulators or inhibitors of Lp-PLA2 and serine hydrolase α-β-hydrolase domain 6 (ABHD6), to be used in pharmaceutical compositions for inhibiting their activity, thereby mitigating inflammatory responses and oxidative stress in warm-blooded animals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If Lp-PLA2 inhibition is used to target inflammatory diseases, then inflammatory tone is reduced, but the mechanism to modulate oxidative stress remains insufficient
Solution Approach 1:
The patent applies multi-functionality by designing compounds that simultaneously inhibit both Lp-PLA2 and ABHD6 enzymes. This dual inhibition allows a single therapeutic agent to address both inflammatory tone modulation (via Lp-PLA2) and oxidative stress modulation (via ABHD6), thereby resolving the contradiction between targeting inflammation and addressing oxidative stress mechanisms
2Reliability
If current treatments are used for ischemia, traumatic brain injury, multiple sclerosis, diabetes, Alzheimer's disease, Parkinson's disease, ALS, and cancer, then disease management is maintained, but effective mechanisms to modulate inflammatory tone and oxidative stress are lacking
Solution Approach 1:
The patent employs parameter changes by modifying the biochemical parameters of lipid metabolism through dual enzyme inhibition. By changing the enzymatic activity parameters of both Lp-PLA2 and ABHD6, the compounds create new therapeutic parameters that simultaneously address inflammation and oxidative stress, enabling effective modulation mechanisms for multiple diseases
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit Lp-PLA2 activity, reducing pro-inflammatory lipid production and oxidative stress, providing therapeutic benefits for the mentioned diseases by modulating inflammatory tone and promoting apoptosis in cancer cells.
Implementation Method 1
Lp-PLA2 is a constitutively active, secreted serine hydrolase enzyme encoded by the PLA2G7 gene that degrades a wide range of phospholipids through phospholipase A2 activity
Implementation Method 2
The serine hydrolase α-β-hydrolase domain 6 (ABHD6) is another lipid mediator
Data Source
AI summary
Provided herein are lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitors, pharmaceutical compositions thereof, and methods of their use for the treatment of disease.